Home/Filings/4/0000902664-21-004738
4//SEC Filing

Matrix Capital Management Company, LP 4

Accession 0000902664-21-004738

CIK 0001501796other

Filed

Nov 3, 8:00 PM ET

Accepted

Nov 4, 4:44 PM ET

Size

11.9 KB

Accession

0000902664-21-004738

Insider Transaction Report

Form 4
Period: 2021-11-02
Transactions
  • Purchase

    Common Stock

    2021-11-02$14.00/sh+1,785,000$24,990,0004,112,870 total(indirect: See footnotes)
  • Conversion

    Series E Convertible Preferred Stock

    2021-11-022,327,8700 total(indirect: See footnotes)
    Common Stock (2,327,870 underlying)
  • Conversion

    Common Stock, par value $0.00001 per share ("Common Stock")

    2021-11-02+2,327,8702,327,870 total(indirect: See footnotes)
GOEL DAVID E.
10% Owner
Transactions
  • Conversion

    Series E Convertible Preferred Stock

    2021-11-022,327,8700 total(indirect: See footnotes)
    Common Stock (2,327,870 underlying)
  • Conversion

    Common Stock, par value $0.00001 per share ("Common Stock")

    2021-11-02+2,327,8702,327,870 total(indirect: See footnotes)
  • Purchase

    Common Stock

    2021-11-02$14.00/sh+1,785,000$24,990,0004,112,870 total(indirect: See footnotes)
Footnotes (3)
  • [F1]The Series E Convertible Preferred Stock was convertible at any time, at the holder's election on a 1-for-1 basis, and did not have an expiration date. The shares of Series E Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering.
  • [F2]The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.
  • [F3]The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Documents

1 file

Issuer

Aura Biosciences, Inc.

CIK 0001501796

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001410830

Filing Metadata

Form type
4
Filed
Nov 3, 8:00 PM ET
Accepted
Nov 4, 4:44 PM ET
Size
11.9 KB